title: Increased thyroid autoimmunity among women with multiple sclerosis in the postpartum setting.
abstract: BACKGROUND
  Multiple sclerosis (MS) patients are predisposed to thyroid abnormalities, but the risk for pregnancy-related thyroid pathology among MS patients has not been evaluated.
  
  
  OBJECTIVE
  The objectives of this research are to prospectively evaluate the prevalence of thyroid autoimmunity among MS patients in relation to pregnancy, and to investigate its impact on pregnancy outcome, postpartum depression and fatigue.
  
  
  METHODS
  Forty-six pregnant MS patients underwent repeat testing for serum thyroid antibodies (Abs), clinical evaluation and thyroid hormone measurement. Results were compared to 35 age-matched healthy mothers.
  
  
  RESULTS
  At six months postpartum 35.3% of MS patients presented elevated levels of thyroid Abs compared to 5.7% of controls, p = 0.01. Mean thyroid Ab concentrations among MS patients were significantly reduced during pregnancy and returned to maximal levels at six months postpartum. The proportion of individuals with postpartum thyroid dysfunction did not differ significantly between MS patients and healthy controls (3.4% vs 2.9%, p = 1.00). Elevated thyroid Ab levels did not increase the risk for adverse pregnancy outcome, fatigue or postpartum depression.
  
  
  CONCLUSIONS
  Considering the tendency of MS mothers to develop thyroid autoimmunity postpartum and in association to treatments, we recommend screening MS patients for thyroid dysfunction (TSH) during early pregnancy and after delivery.
authors: Department of Neurology, Turku University Hospital, Finland.
authors: A
authors: A
authors: Jalkanen
authors: M
authors: M
authors: Saraste
authors: A
authors: A
authors: Gfeller
authors: H M
authors: HM
authors: Surcel
authors: L
authors: L
authors: Airas
mesh_terms: D000328:Adult; D000906:Antibodies / Q000097:blood; D016022:Case-Control Studies; D036861:Delivery, Obstetric; D019052:Depression, Postpartum / Q000453:epidemiology / Q000523:psychology; D005221:Fatigue / Q000175:diagnosis / Q000453:epidemiology; D005260:Female; D006801:Humans; D009103:Multiple Sclerosis / Q000150:complications* / Q000453:epidemiology / Q000276:immunology*; D020528:Multiple Sclerosis, Chronic Progressive / Q000150:complications / Q000276:immunology; D050032:Postpartum Thyroiditis / Q000453:epidemiology* / Q000276:immunology*; D011247:Pregnancy; D011256:Pregnancy Outcome; D015995:Prevalence; D011446:Prospective Studies; D012008:Recurrence; D012306:Risk; D013256:Steroids / Q000009:adverse effects / Q000627:therapeutic use; D013954:Thyroglobulin / Q000276:immunology; D013960:Thyroid Function Tests; D013967:Thyroiditis, Autoimmune / Q000453:epidemiology* / Q000276:immunology*; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000097:blood
chemical_list: D000906:Antibodies; D013256:Steroids; D013972:Thyrotropin; D013954:Thyroglobulin; D013974:Thyroxine
keywords: Multiple sclerosis; postpartum thyroiditis; pregnancy; thyroid antibodies